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Nosocomial or hospital acquired infections threaten the survival and neurodevelopmental outcomes of infants
admitted to the neonatal intensive care unit, and increase cost of care. Premature infants are particularly vulnerable
since they often undergo invasive procedures and are dependent on central catheters to deliver nutrition and on
ventilators for respiratory support. Prevention of nosocomial infection is a critical patient safety imperative, and
invariably requires a multidisciplinary approach. There are no short cuts. Hand hygiene before and after patient
contact is the most important measure, and yet, compliance with this simple measure can be unsatisfactory.
Alcohol based hand sanitizer is effective against many microorganisms and is efficient, compared to plain or
antiseptic containing soaps. The use of maternal breast milk is another inexpensive and simple measure to
reduce infection rates. Efforts to replicate the anti-infectious properties of maternal breast milk by the use of probiotics,
prebiotics, and synbiotics have met with variable success, and there are ongoing trials of lactoferrin, an iron binding
whey protein present in large quantities in colostrum. Attempts to boost the immunoglobulin levels of preterm infants
with exogenous immunoglobulins have not been shown to reduce nosocomial infections significantly. Over the last
decade, improvements in the incidence of catheter-related infections have been achieved, with meticulous attention
to every detail from insertion to maintenance, with some centers reporting zero rates for such infections. Other
nosocomial infections like ventilator acquired pneumonia and staphylococcus aureus infection remain problematic, and
outbreaks with multidrug resistant organisms continue to have disastrous consequences. Management of infections is
based on the profile of microorganisms in the neonatal unit and community and targeted therapy is required to control
the disease without leading to the development of more resistant strains.
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Background
Advances in neonatal care have lead to the increasing
survival of smaller and sicker infants, but nosocomial in-
fections (NI), also known as health care associated or
hospital acquired infections continue to be a serious
problem. Late-onset sepsis (LOS), or sepsis acquired
after 72 h of life, with the exception of Group B strepto-
coccal or Herpes simplex virus infection, is usually hos-
pital acquired, particularly in infants who are
hospitalized from birth. These infections are associated
with increased mortality rates, immediate and long term
morbidity, prolonged hospital stay and increased cost of
care [1–3]. Efforts to eradicate neonatal NI have had
limited success in some areas, but many remain in-
transigent, and outbreaks with multi – drug resistant or-
ganisms (MDRO) continue to occur in neonatal
intensive care units (NICUs) worldwide.
Risk of NI in preterm, late preterm and term
infants
Prematurity is the most important risk factor for NI. In
the United States, surveillance data over almost 2 de-
cades from the National Institute of Child Health and
Human Development (NICHD) Neonatal Network
show that 20–25% of very low birth weight (VLBW,
birth weight ≤ 1500 g) infants who survived beyond
3 days were found to have one or more episodes of
blood culture proven sepsis, with the majority being
caused by gram-positive organisms, predominantly co-
agulase-negative staphylococci (CONS) (Table 1) [1–3].
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The rate of infections was inversely related to birth weight
and gestational age, with 50% of the infections occurring
in infants born at <25 weeks or weighing less than 750 g
at birth. Considerable center to center variability in the in-
cidence of late-onset sepsis has been noted with rates of
LOS ranging from 10.6 to 31.7%, despite adjusting for
birth weight, GA, race and sex [2].
There has been some progress recently in tackling
neonatal NI. NICHD surveillance data showed that
rates of LOS decreased from 2005 to 2012 for infants
of each gestational age, (eg for infants born at
24 weeks, it decreased from 54 to 40%, and for those
born at 28 weeks, the decrease was from 20 to 8%)
[4]. Comparable decreases in the rates of LOS in
preterm VLBW infants was noted in 669 North
American Hospitals in the Vermont Oxford Network,
with rates of LOS decreasing from 21% in 2000 to
15% by 2009 [5]. A similar analysis of LOS in pre-
term infants born at <32 weeks gestation in 29
NICUs in the Canadian Neonatal Network showed
that 15% of infants developed LOS, with 80% of these
infection being gram-positive, chiefly CONS [6].
The incidence of LOS in late preterm infants, born at
34 to 36 weeks gestational age and in term infants is
much lower. A large study of more than 100,000 late
preterm infants admitted to 248 NICUS in the United
States between 1996 and 2007 showed an incidence of
6.3 episodes of LOS per 1000 NICU admissions; with
59.4% caused by gram-positive organisms, predomin-
antly CONS, 30.7% by gram-negative organisms and
7.7% by yeast [7]. In term infants (≥37 weeks gestational
age) discharged from NICUs from 1997 to 2010, the rate
of late-onset bloodstream infections was 2.7/1000 admis-
sions, with similar pathogens [8].
Apart from prematurity, prolonged duration of paren-
teral alimentation with delayed enteral nutrition, intra-
vascular catheterization, extended respiratory support on
ventilators, gastrointestinal surgery, and use of broad
spectrum antibiotics are recognized risk factors for neo-
natal NI [2]. The very devices that sustain life and pro-
vide sustenance to premature and/or sick newborns
admitted to the NICU may become channels for bacter-
ial invasion, with fragile skin, and immaturity of immune
systems exacerbating the risk.
The most common NI in NICUs are bloodstream in-
fections, often catheter -related (central line associated
bloodstream infection, CLABSI), followed by Ventilator-
Associated Pneumonias (VAP), surgical site infections
and less frequently catheter associated urinary tract
infections, and ventricular shunt infections. Skin and
soft tissue infections may also be hospital acquired in
newborn infants [9].
Outbreaks of NI have been related to overcrowding,
understaffing, and contamination of equipment, environ-
ment, medications, and even breast milk [10–13].
Organisms responsible for infections
The microorganisms responsible for NI may be the pa-
tient’s own microflora, present on the skin, nasopharynx
and gastrointestinal tract, or the transmission of microor-
ganisms from visitors and caretakers. Recent studies have
shown that infants with a less diverse gut microbiome har-
bor pathogenic bacteria in the gastrointestinal tract which
may translocate across the epithelial barrier, predisposing
them to late-onset bloodstream infections [14, 15].
Table 1 shows the distribution of organisms respon-
sible for LOS in NICHD Neonatal Network NICUs over
the years. In resource-limited countries, gram-negative
bacteria such as E. Coli, Klebsiella, Acinetobacter and
Pseudomonas are the predominant bacteria responsible
for NI in neonatal units, and a very high prevalence of
antibiotic resistance has been described [16].
Although much attention has been paid to hospital ac-
quired bacterial infections, with the availability of better
diagnostic methods, nosocomial viral infections are in-
creasingly being recognized. Respiratory syncytial virus,
influenza and parainfluenza viruses are well known for
nosocomial transmission, but rhinovirus has recently
been identified as an important nosocomial pathogen in
preterm infants [17]. Nosocomial viral respiratory infections















Staphylococcus aureus 9 8 11
Enterococcus/Group D strep 5 3 4
Group B streptococcus 2 2 2
Other 2 9 7
Gram-negative
Enterobacter 4 3 3
Escherichia coli 4 5 5
Klebsiella 4 4 4
Pseudomonas 2 3 2
Other 4 1 2
Fungi
Candida albicans 5 6 5
Candida parapsilosis 2 4 2
Other 2 2 1
Numbers are expressed in percentages
Abbreviations NICHD NRN National Institutes of Child Health and Human
Development Neonatal Research Network, VLBW Very low birth weight, birth
weight ≤1500 g
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result in escalation of respiratory support, prolonging
length of stay, hospitalization costs and also lead to affected
infants requiring home oxygen twice as often as unaffected
infants [17]. Rotavirus, adenovirus and norovirus have been
responsible for outbreaks of gastrointestinal illness in NICU
patients, and have been implicated in clusters of NEC cases
[18]. Human parechovirus infections can present with
sepsis like syndromes, indistinguishable from bacterial
infection, and with symptoms of meningoencephalitis.
In a prospective cohort study of preterm infants with
suspected LOS over an 18 month period, 13% of in-
fants tested were found to have evidence of parecho-
virus by reverse transcriptase polymerase chain reaction,
confirmed by DNA sequencing [19].
Prevention of neonatal NI
The “All or None” approach of process quality is an im-
portant concept to understand and implement in pre-
vention of NI [20]. NI are usually multifactorial and
preventative strategies entail multiple interventions or a
series of steps which operate synergistically. Partial
execution of a series of steps may be ineffective. For ex-
ample, insertion of a central line using strict aseptic
techniques would be vitiated by improper line care,
resulting in CLABSI. Hence, the proposal of “bundles” – a
set of evidence based processes, that when instituted as a
group, improve outcomes. This has been found to be par-
ticularly effective in reducing CLABSIs in NICUs [21].
Among the interventions to prevent neonatal NI, some
that appear quite simple (hand hygiene, feeding maternal
breast milk) have been shown to be surprisingly effective,
while others have not lived up to their theoretical promise
(intravenous immunoglobulin), and a few are still being
evaluated (lactoferrin). The cornerstone of infection pre-
vention in any setting is hand hygiene.
Hand hygiene
Hand hygiene is the single most important intervention
in interrupting the transmission of microorganisms and
thus preventing NI. Bacterial counts on hands of health
care workers range from 3.9 × 104 to 4.6 × 106 colony
forming units/cm2, and may include pathogens such as
staphylococcus aureus, klebsiella pneumoniae, entero-
bacter, acinetobacter and candida [22]. Viable organisms
are present on the skin squames that humans shed daily,
and these contaminate patient clothing, bed linen and
furniture, with transmission by health care workers’
hands if they are not cleaned before and after patient
contact. Although this intervention appears simple, im-
plementation is often more challenging than expected,
with low compliance rates even in intensive care areas
[21]. There is now a global effort to improve hand hy-
giene compliance with the WHO “Clean Care is Safer
Care” campaign [23]. A multipronged effort is required
to improve compliance, with education of education of
health care workers, performance feedback, reminders,
use of automated sinks and introduction of an alcohol
based hand rub [24]. It is believed that the introduction
of the alcohol based hand rub has revolutionized hand
hygiene practice, since it takes less time, improves com-
pliance and has shown to be effective in many settings.
Table 2 illustrates the mode of action and efficacy of
commodities commonly used for hand hygiene. Apart
from health care workers, parents and siblings may also
be responsible for transmission of infection [25], so hand
hygiene should be emphasized for all visitors/caregivers
in the NICU.
Artificial finger nails worn by health care providers
have been associated with persistent carriage of Pseudo-
monas aeruginosa, Klebsiella pneumoniae and fungi, and
linked to outbreaks with these organisms in intensive
care settings [26, 27]. The Hospital Infection Control
Practices Advisory Committee (HICPAC) guidelines
recommend that health care providers with direct pa-
tient contact in intensive care areas should not wear
artificial nails [28]. It is unclear if the use of nail polish
is associated with NI [29].
Early feeding and human milk
Since the seminal paper by Narayanan et al. in 1984
that showed that feeding raw unpasteurized maternal
milk was associated with lower rates of sepsis in low
birth weight infants in India [30], numerous studies
in industrialized countries have confirmed that feed-
ing human milk is associated with lower rates of sep-
sis and necrotizing enterocolitis in preterm and very
low birth weight infants [31–33]. Early enteral feed-
ing, within 2 to 3 days of life, has been associated
with lower rates of NI, without increasing rates of
necrotizing enterocolitis [34]. In addition, human milk
is better tolerated than bovine formula, and is associ-
ated with establishment of complete enteral nutrition
at a faster rate, allowing early discontinuation of cen-
tral catheters [35]. The advantages of maternal breast
milk in preventing NI have not been duplicated by
the use of donor milk [31]. Human milk contains
secretory antibodies, phagocytes, lactoferrin and pre-
biotics which improve host defense and gastrointestinal
function. A recent review delineates compositional and
bioactive differences between mother’s own milk and
donor milk which may account for the differences in
outcome [36]. It is important to note that human milk
can also be associated with outbreaks of infection in
NICUs, either due to milk sharing [13] or contamin-
ation of equipment such as milk warmers, or collection
pumps [12].
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Central line care
Central venous catheters provide stable intravenous ac-
cess to sick or low birth weight infants who need long
term intravenous nutrition or medications, and umbilical
arterial catheters are used for blood sampling and con-
tinuous blood pressure monitoring. These central lines
are ubiquitous, and usually essential in the NICU, but
increase the risk of NI by breaching the protective skin
barrier and due to the propensity of many microorganisms
to form a biofilm [37]. CLABSI are a subset of NI, defined
by the Centers for Disease Control and Prevention’s
National Healthcare Safety Network (NHSN) as a blood-
stream infection in which the initial positive culture oc-
curs at least 2 days after placement of a central line that is
in situ or was removed less than 2 days before the positive
culture, and the positive blood culture was not attributable
to infection at another site [38]. Evidence based care of
central lines has resulted in a decrease of CLABSI over
the last decade (Table 3). These care “bundles” are not
complicated, but require training, commitment, and con-
stant vigilance to maintain compliance. There is still sig-
nificant heterogeneity in CLABSI prevention practices in
NICUs in the United States, and in other countries,
with some centers using chlorhexidine for skin anti-
sepsis or for dressings and some centers restricting
the use of chlorhexidine to larger infants based on
United States Food and Drug Administration guide-
lines [39, 40]. Nevertheless, from 2007 to 2012, rates
of CLABSIs decreased in NICUs in the United States
from 4.9 to 1.5 per 1000 central line days [41], with
some centers achieving sustained reductions to zero
rates [42, 43]. In lower resource countries, CLABSI
rates in NICUs participating in the International
Nosocomial Infection Control Consortium are reported to
be 10 to 20 times higher than those in NICUs reporting
data to the CDC NHSN [44].
Fluconazole prophylaxis
Candida species colonize the skin and mucous mem-
branes of 60% of critically ill neonates and can rapidly
progress to invasive infection, with fungal infections being
the 3rd most common cause of NI in neonates [45, 46].
Prematurity, low birth weight, use of cephalosporin antibi-
otics, exposure to more than 2 antibiotics, exposure to H2
blockers, gastrointestinal surgery, parenteral nutrition use
>5 days, use of lipid emulsion for >7 days, lack of enteral
feeding and presence of a central catheter have all been
associated with increased risk of invasive candidiasis, and
in extremely low birth weight infants (< 1000 g), inva-
sive candidiasis has been associated with 73% mortality
or neurodevelopmetal impairment [47]. Fungal infec-
tion accounted for 9% of cases of LOS in VLBW infants
in 1996 [1], but more recent studies indicate that inva-
sive candidiasis has decreased in NICUs in the United
States since 1997, probably secondary to the widespread
use of fluconazole prophylaxis and decreased use of
broad spectrum antibacterial antibiotics [48]. In a study
of data from 709,325 infants at 322 NICUS managed by
the Pediatrix Medical Group from 1997 to 2010, the
annual incidence of invasive candidiasis among infants
with a birth weight of 750–999 g decreased from 24.2
to 11.6 episodes per 1000 patients, and from 82.7 to
23.8 episodes per 1000 patients among infants with a
birth weight <750 g. Fluconazole prophylaxis increased
among all VLBW infants over the years, with the largest
increase among infants weighing <750 g at birth, in-
creasing from 3.8 per 1000 infants in 1997 to 110.6 per
1000 infants in 2010. The use of broad spectrum anti-
bacterial antibiotics decreased concomitantly in all in-
fants, from 275.7 per 1000 patients in 1997 to 48.5 per
1000 patients in 2010 [48].
Prophylactic antifungal therapy reduces colonization
of the skin, gastrointestinal and respiratory tracts and
Table 2 Hand hygiene: materials and efficacy
Agent Plain soap Antimicrobial soap with chlorhexidine Alcohol based hand sanitizer








0.6 to 1.1 log10 CFU 2.1 to 3.0 log10 CFU; has persistent
residual antiseptic activity on the
skin which may last up to 30 min.
3.2 to 5.8 log10 CFU
Effective against Dirt, organic material Gram-positive cocci Gram-positive cocci, gram-negative
bacilli, mycobacterium tuberculosis,
fungi, viruses
Less effective against Gram-negative bacilli, fungi and
viruses, mycobacteria, spore
forming bacteria such as
Clostridium difficile
Clostridium difficile,
Hepatitis A, rotavirus, enteroviruses,
adenovirus, spores
Comments Trauma caused by frequent
skin washing may lead to
chapping of skin and shedding
of resistant flora
Optimal antimicrobial activity at
concentration of 60–90%
(from ref [21] and [28])
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prevents invasive candida infection in high risk preterm
infants [46, 47, 49]. Prophylaxis with intravenous flucon-
azole at 3 mg/kg twice a week, has been recommended
for preterm infants with birth weight < 1000 g or gesta-
tional age ≤ 27 weeks gestation, starting within the first
2 days after birth, and continued until there is no neces-
sity for central and peripheral intravenous access. In
infants weighing 1000–1500 g, prophylaxis may be con-
sidered by individual NICUs with high rates of invasive
candidiasis [49]. There has been no evidence of develop-
ment of resistance to fluconazole with this regimen in
neonates, although increasing fluconazole resistance has
been documented in adult intensive care units. Oral
nystatin has also been shown to be effective for prophy-
laxis [50], but it cannot be used when infants have ileus,
necrotizing enterocolitis or intestinal perforation, all
conditions with a high risk of invasive candida infection.
The use of routine fluconazole prophylaxis has been
challenged more recently, in a randomized controlled
trial in infants weighing <750 g at birth, which showed
that although invasive candidiasis occurred less fre-
quently in the fluconazole group (3% [95% CI: 1 to 6%])
versus the placebo group (9% [95% CI: 5–14%]), there
was no difference in the composite endpoint of death
and invasive candidiasis or in the rates of neurodevelop-
mental impairment [51].
Table 3 Guidelines for prevention of intravascular catheter associated infections
Education and training:
Educate health care personnel regarding indications for intravascular catheter use, proper procedures for the insertion and maintenance of intravascular
catheters and appropriate infection control measures
Periodically reassess knowledge of and adherence to guidelines for all personnel involved in the insertion and maintenance of intravascular catheters
Designate only trained personnel who demonstrate competence for the insertion and maintenance of central intravascular catheters.
Catheter placement and duration of use
Weigh the risks and benefits of placing a central venous catheter.
Evaluate daily if catheter is still necessary
Promptly remove any intravascular catheter that is no longer essential
Remove and do not replace umbilical artery catheters if any signs of catheter-related bloodstream infection, vascular insufficiency in the lower
extremities or thrombosis are present. Optimally umbilical catheters should not be left in place > 5 days.
Remove and do not replace umbilical venous catheters if any signs of CLABSI or thrombosis are present. Umbilical venous catheters should be
removed as soon as possible but can be used up to 14 days if managed aseptically.
Placing catheters
Hand hygiene should be performed before and after palpating catheter insertion sites as well as before and after inserting, replacing, or dressing
an intravascular catheter.
Maintain aseptic technique for insertion and care of intravascular catheters.
Maximum sterile barrier precautions including the use of a cap, mask, sterile gown, sterile gloves and a sterile large drape are necessary for the
insertion of a central venous catheter.
A minimum of a cap, mask, sterile gloves and a small sterile fenestrated drape should be used during peripheral arterial catheter insertion.
Prepare insertion site with povidone iodine/chlorhexidine containing antiseptic (no recommendation can be made about the safety of
chlorhexidine in infants < 2 months)
Use sterile gauze or sterile, transparent semi-permiable dressing to cover catheter site.
Do not use topical antibiotic ointment or creams on insertion sites because of potential to promote fungal infections and antimicrobial resistance.
Do not administer systemic antimicrobial prophylaxis routinely before insertion or during use of an intravascular catheter to prevent catheter
colonization or CLABSI.
Dressing catheters
Use sterile gloves when changing the dressing
Replace catheter site dressing if the dressing becomes damp, loose or visibly soiled.
Catheter care
Use the minimum number of ports or lumens essential for management of the patient
Do not submerge the catheter or catheter site in water.
Minimize contamination risk by scrubbing the access port with an appropriate antiseptic (chlorhexidine, povidone iodine, an iodophor, or 70% alcohol)
and accessing the port only with sterile devices.
Replace tubing used to administer blood, blood products, or fat emulsions (those combined with amino acids and glucose or infused separately)
within 24 h of initiating the infusion.
from ref [38]
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Use of topical emollients
Topical emollients such as vegetable oils or aquaphor
have been postulated to improve skin integrity and bar-
rier function and thereby prevent invasive infection. A
recent Cochrane meta-analysis of 18 primary publica-
tions involving 3089 infants did not provide evidence
that the use of emollient therapy prevents invasive infec-
tion or death in preterm infants in high, middle or low
income settings [52].
Ventilator-Associated Pneumonia (VAP)
Ventilator-associated pneumonia is defined by using a
combination of clinical, radiologic and laboratory criteria
in a patient who has been on assisted ventilation through
an endotracheal or tracheostomy tube for at least 48 h be-
fore the onset of illness. However, these criteria are sub-
jective and frequently have common characteristics with
other diseases, particularly in low birth weight infants with
chronic lung disease. Rates of VAP range from 0 to more
than 50 per 1000 ventilator days in various publications,
reflecting differences in study patients and definitions. It is
also unclear if cultures of tracheal secretions are truly rep-
resentative of VAP or only indicate colonization. In 2012,
the Neonatal and Pediatric Ventilator Associated Events
working group recognized that the current VAP surveil-
lance definition is of questionable utility and meaning in
the neonatal population and refinements are being sought
[53]. While absolute definitions may be lacking, it is well
known that endotracheal intubation leads to impairment
of mucociliary clearance and the potential for colonization
of the endotracheal tube and trachea, from both endogen-
ous and exogenous sources, which may then descend fur-
ther and result in pneumonitis [54]. Endogenous sources
of colonization are oropharyngeal secretions, and aspir-
ation of stomach contents. Exogenous sources include
transmission of infection from a health care workers’
hands, contamination of suction apparatus, airway cir-
cuits, humidifiers, etc. In neonatal patients diagnosed with
VAP, polymicrobial and gram-negative organisms appear
to be predominant, although staphylococcus aureus and
candida have also been noted [55].
VAP prevention “bundles”, similar to CLABSI preven-
tion bundles, have been used in adult ICUs with success,
but many of the interventions are not applicable in neo-
nates [54]. Interventions with potential benefit in neo-
nates are indicated in Table 4. There are few studies
showing the impact of infection control measures in
reducing VAP rates in NICUs [56, 57].
Adjuvant therapy
Immunoglobulin therapy
Preterm infants are deficient in immunoglobulin G (IgG)
since transplacental transport of maternal IgG is trun-
cated by early delivery, and endogenous production
starts only around the third month of life. Polyclonal
intravenous immunoglobulin (IVIG) has been evaluated
to determine if passive immunotherapy is efficacious in
preventing neonatal NI in preterm or low birth weight
(<2500 g birth weight) patients. A 2013 Cochrane review
summarizing 19 studies enrolling almost 5000 preterm
and/or low birth weight patients concluded that when
all studies were combined, there was a 3% reduction in
sepsis and a 4% reduction in one or more episodes of
any serious infection, but was not associated with reduc-
tions in other clinically important outcomes, including
mortality [58]. The Cochrane review’s final statement
was “the decision to use prophylactic IVIG will depend
on the costs and the values assigned to the clinical out-
comes”, and that no additional trials to test the efficacy
of previously studied IVIG preparations are warranted.
Since Staphylococci, especially CONS, are responsible
for the majority of late-onset infections in VLBW infants,
IVIG preparations containing various type specific anti-
bodies targeting different antigenic sites were developed,
but studies of these products (Veronate or INH-A21: anti-
body against microbial surface components recognizing
adhesive matrix molecules, Altastaph: antibody against
capsular polysaccharide antigen type 5 and 8, and Pagi-
baximab: anti-lipoteichoic human chimeric monoclonal
antibody) have also shown disappointing results [59, 60].
IgM-enriched immunoglobulins are being evaluated as ad-
juvant therapy for VLBW infants with proven sepsis, but
not for prophylaxis [61].
Lactoferrin
Lactoferrin is an iron – binding glycoprotein present in
mature human milk at a concentration of 1 to 3 g/L and
in colostrum at 7 g/L. Lactoferrin limits the amount of
iron available to pathogenic bacteria, promotes growth
of commensal bacteria, and with lysozyme, another
Table 4 Interventions to prevent VAP in Neonates
Definite or probable benefit Unclear benefit
Caregiver education Oral care with antiseptic
or colostrum
Hand hygiene Elevation of head of bed
Wear gloves when in contact
with secretions
In-Line (closed) suctioning





Change ventilator circuit only when
visibly soiled or malfunctioning
Remove condensate from
ventilator circuit frequently
Modified from ref [54]
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antibacterial present in human milk, is involved in the
destruction of gram negative bacteria [36]. Delay in es-
tablishing enteral nutrition exacerbates the low lactofer-
rin levels in preterm infants. Bovine lactoferrin, which is
70% homologous with human lactoferrin, has high anti-
microbial activity, and is available commercially as a
food supplement, has shown promise in reducing the in-
cidence of late-onset sepsis in VLBW infants, particu-
larly in infants weighing <1000 g at birth [62]. There are
ongoing trials which may provide additional evidence of
the effectiveness of this intervention before this becomes
common practice [63].
Probiotics
In babies born at term by vaginal delivery, the gut is col-
onized with probiotic bacteria from the mother such as
lactobacilli and bifidobacteria which are crucial to the
development of the intestinal mucosal immune system.
Preterm neonates have abnormal intestinal colonization,
often with pathogenic bacteria and have low numbers
of probiotic bacteria. Efforts to repopulate the preterm
infant’s gut with probiotics in an effort to decrease late-
onset sepsis have resulted in variable success, and met-
analysis of trials have given inconsistent results. A
Cochrane metanalysis in 2014 of 16 eligible trials with
5338 patients concluded that probiotic supplementation
did not result in statistically significant reduction of
LOS in preterm infants [64]. A more recent metanalysis
of 37 randomized controlled trials with 9416 patients
showed that probiotics significantly reduced the risk of
LOS (13.9% versus 16.3%, number needed to treat =44),
but of all the studies analyzed, the two largest trials did
not show a significant reduction in the rates of LOS
with probiotics [65]. In the ProPrems study [66], 1099
preterm VLBW infants in Australia and New Zealand
were randomized to receive a probiotic combination of
Bifidobacterium infantis, Streptococcus thermophilus
and Bifidobacterium lactis or placebo. Breast milk feed-
ing rates were high (96.9%) among these infants. No
significant difference was found in definite late onset
sepsis or all cause mortality, but the rate of Stage 2 nec-
rotizing enterocolitis was reduced (2% versus 4.4%).
The Probiotics in Preterm Infants Study Collaborative
(PiPs trial) [67] in the United Kingdom recruited 1315
infants of whom 650 were administered the probiotic
Bifidobacteium breve BBG-001. There was no signifi-
cant difference in the incidence of LOS in the probiotic
patients (11%) versus the controls (12%) and the rates
of NEC were also similar.No adverse effects have been
noted in these trials, but there have been case reports
of bacteremia in preterm infants originating from pro-
biotic therapy [68]. Despite numerous trials and met-
analyses, questions remain about the effectiveness of
probiotics, the strains to be used, appropriate dosage, etc.
Prebiotics
Human milk oligosaccharides (HMO) are complex car-
bohydrates which promote the growth of beneficial com-
mensals like Bifidobacterium and Bacteroides in the
healthy breast fed term infants’ intestine. Most patho-
genic Enterobacteriaceae lack specific glucosidases to
utilize these oligosaccharides as a food source. In
addition, HMOs have structural homology to many cell
surface glycans and act as decoys by binding luminal
bacteria that are then unable to bind to the luminal
enterocytes. HMOs produced by mothers may vary in
structure and may influence the intestinal microbiota of
their infants [69]. Prebiotics are non-digestible dietary
products that selectively stimulate the growth or activ-
ity of beneficial commensal bacteria similar to HMOs,
but the complexity of this approach to altering gut
microbiota is only just beginning to be understood [70].
Synthetic prebiotics such as short chain galacto oligo-
saccharides, long chain fructo-oligosaccharides, inulin,
lactulose are available and have been used in combina-
tions to mimic natural human milk oligosaccharides. A
metanalysis of 7 trials including 417 patients showed
that supplementation with prebiotics resulted in signifi-
cantly higher growth of beneficial microbes but did not
decrease the incidence of sepsis, NEC or reduce the
time to full feeding [71].
Synbiotics
A synbiotic is a product that contains both a probiotic
microbe and a prebiotic substrate. There is experimental
evidence that the simultaneous administration of probio-
tics and prebiotics can improve survival of the probiotic
bacteria, but there is no clinical evidence yet that synbio-
tics are useful in preventing neonatal NI [72].
Antibiotic stewardship
Empirical antibiotic use is widespread in neonatal inten-
sive care units. A recent review of over 50,000 patients
in 127 California NICUs showed a 40 fold variation in
antibiotic prescribing practices, despite similar burdens
of proven infections, NEC, surgical volume and mortality
[73]. Prolonged initial empirical antibiotic treatment in
preterm infants has been associated with increased rates
of LOS, NEC and death, with each additional empirical
treatment day associated with measureable increase in
risk [74, 75]. Perinatal and early empiric antibiotic use
has been associated with lower bacterial diversity in the
developing microbiome of the neonate, and increased
colonization with potentially pathogenic Enterobacteri-
aceae, which may precede bloodstream infection in pre-
term infants [14, 15, 76, 77]. Widespread antibiotic use,
particularly with broad spectrum cephalosporins potenti-
ates the development of resistant strains, and increased
colonization and invasive disease due to candida [78].
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The gravity of this scenario has been recognized and given
impetus to develop local and national antibiotic steward-
ship programs [79]. However, a prospective longitudinal
study of neonatal infections and antibiotic use over
25 years in a tertiary NICU showed that emergence of
cephalosporin resistant gram-negative bacterial infection
was not prevented by responsible antibiotic use, indicating
that the relationship between antimicrobial use and drug
resistance is complex and that other factors may be in-
volved [80].
Management of neonatal nosocomial infections
Infants in the NICU may deteriorate rapidly when they
develop NI, so vigilance and high index of suspicion for
sepsis is essential. Management includes appropriate
diagnostic tests including blood, and whenever possible,
cerebrospinal fluid cultures, followed by antibiotic ther-
apy and supportive care.
Initial antibiotic therapy is empirical and targeted
against the most likely organisms, based on the clinical
presentation, available epidemiological information on
the pathogen profile in the neonatal unit where the pa-
tient is being treated and in the community [81, 82].
Antibiotic therapy should be narrowed down or modi-
fied as soon as culture and antibiotic susceptibility re-
sults are available. In infants suspected to have CLABSI,
most NICUs use a regimen of vancomycin and gentami-
cin as initial therapy, to cover the possibility of CONS or
a gram-negative infection. However, the use and overuse
of vancomycin as the first line of treatment for sus-
pected LOS in NICU patients has led to the emergence
of vancomycin resistant enterococci. There is a recom-
mendation that neonatal units consider starting empir-
ical treatment with oxacillin or flucloxacillin instead of
vancomycin, together with an aminoglycoside such as
gentamicin in infants who are suspected to have
CLABSI, but are not severely ill, since CONS sepsis is
rarely severe and there would be time to switch to
vancomycin if the strain is resistant to the initial treat-
ment [82]. There is no evidence that a delay in vanco-
mycin therapy increases mortality in infants with CONS
sepsis [83]. On the other hand, inadequate empirical
therapy for MRSA bloodstream infection has been associ-
ated with increased mortality, so the judicious selection of
initial antibiotics remains critical, but still challenging,
since clinical signs are usually non-specific [84]. Gram-
negative septicemia and candidemia are often associated
with hypotension, thrombocytopenia and acidosis. When
gram-negative sepsis is strongly suspected or confirmed,
or in the presence of gram-negative meningitis, the
addition or substitution of a 3rd generation cephalosporin
is justified. Pipercillin–tazobactam may be considered to
provide coverage for resistant gram-negative organisms.
In infections with extended spectrum beta-lactamase
(ESBL) producing organisms, or in critically ill infants
with complicated intra-abdominal infections, a carba-
penem antibiotic may be considered [82, 85]. A combin-
ation of antibiotics is usually used in critically ill infants
with necrotizing enterocolitis (NEC) or complicated intra-
abdominal infections, where polymicrobial infection with
aerobic and anaerobic microorganisms is probable [85].
Results of the ongoing Phase 2/3 study (SCAMP study,
NCT 01994993) of different antibiotic regimens for com-
plicated intra-abdominal infections in infants may help
guide future therapy. Anaerobic therapy with clindamycin,
metronidazole, carbapenems etc. in infants with NEC has
been associated with an increase in intestinal strictures,
but with lower mortality in infants with surgical NEC [86].
Invasive neonatal candidiasis is treated with amphotericin
B deoxycholate, fluconazole or micafungin [87], although
some authors suggest reserving fluconazole only for
prophylaxis and using amphotericin for treatment to pre-
vent the emergence of resistant strains [49].
In addition to appropriate antibiotics, consideration
should be given to removal of central lines since there
is an increased risk of infectious complications and per-
sistently positive cultures if the central line is not re-
moved promptly in bacteremic patients or in patients
with candidemia [88]. One positive blood culture for
Staph aureus, or Gram-negative rods or Candida war-
rants removal of the central line. Medical management
without central line removal may be considered if there
is one positive CONS culture, but if cultures are repeatedly
positive, the central catheter should be removed, with
placement of a new catheter if required, once cultures are
negative.
Supportive care for infants with NI includes respira-
tory, hemodynamic, hematological and nutritional sup-
port in the NICU, and close follow up post–discharge
with early intervention services since these infants are at
increased risk for neurodevelopmental delays [89].
Control of outbreaks
Apart from endemic infections, outbreaks of bacterial,
fungal and viral infections have been reported in NICUs,
with serious consequences for patients, huge economic
burdens and staffing issues [10, 11, 90]. An analysis of a
world wide database of health care associated infections
(https://www.outbreak-database.com) showed that
NICUs account for 38% of outbreaks in ICUs and 18%
of all published outbreaks, and this probably represents
only the tip of the iceberg [10]. Klebsiella, Staphylococ-
cus, including MRSA, Serratia, and Enterobacter species
were responsible for the majority of reported outbreaks.
ESBL producing Enterobacteriaceae have emerged as
major pathogens responsible for outbreaks of infection
in NICUs with associated significant mortality [11]. A
recent review of 75 studies reported 1185 cases of
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colonization and 860 infected with 16% mortality in in-
fected infants. Klebsiella pneumoniae was the most fre-
quently implicated pathogen. The source of the outbreak
was unknown in 57% of the reports; the most commonly
identified source was admission of an ESBL colonized
infant with subsequent horizontal dissemination. Under-
staffing was identified as a major risk factor in most
studies, but the intervention most commonly imple-
mented to terminate outbreaks was enhanced infection
control measures including hand hygiene, contact pre-
cautions, patient cohorting/isolation, and environmental
cleaning. In 23% of reports, the outbreak of ESBL infec-
tion led to ward closure. Most units do not routinely
screen infants for ESBL infection. Some countries have
adopted more rigorous routine screening measures to
identify infants colonized with pathogens, in order to
prevent horizontal transmission [91].
Staphylococcus aureus is the second most common
cause of late-onset sepsis in VLBW infants [3], and is
often implicated in outbreaks [10]. Neonates quickly be-
come colonized after birth from their adult caregivers,
and colonization may be precursor to invasive infection.
In one study, 34% of mothers were colonized with
Staphylococcus aureus, and, the cumulative incidence of
S. aureus acquisition in infants born to carrier mothers
was 42.6/100 within 72–100 h after birth, rising to 69.7/
100 at 1 month follow up [92]. The emergence and rapid
rise of methicillin resistant staphylococcus aureus
(MRSA) infections caused considerable alarm, but large
studies have shown that methicillin sensitive staphylo-
coccus aureus (MSSA) causes more infections and more
deaths than MRSA and infection prevention strategies
should consider MSSA as well as MRSA [93]. Strategies
to prevent MRSA transmission in NICUs have included
identifying and cohorting colonized neonates, placing
them on contact precautions, enhanced hand hygiene
compliance, decolonization of colonized neonates and/
or health care workers with topical mupirocin, and use
of chlorhexidine baths for patients as well as for health
care workers [94]. Following two outbreaks of Staphyloc-
cus aureus infections, one NICU instituted a regimen of
prophylactic mupirocin applied to all infants admitted to
the NICU throughout hospitalization and found that
both MRSA and MSSA colonization decreased from
60% to < 5% [95]. In another level 3 NICU, rigorous at-
tempts at preventing colonization and transmission
were inadequate with infants developing infection be-
fore being identified as colonized or after attempting
decolonization [96].
Conclusion
The prevention and treatment of nosocomial infec-
tions continues to be a complex process with no easy
solutions. There have been improvements in some
areas with documented improvement in rates of
CLABSI, but a number of infections remain difficult
to control or eradicate. There are isolated case reports
as well as outbreaks of infection with increasingly re-
sistant strains or infections with unusual pathogens.
Although there are limitations to the diagnostic and
therapeutic arsenal available presently to tackle these
infections, much can be achieved by attention to sim-
ple preventive measures such as hand hygiene and use
of maternal breast milk.
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